Physician

Clara Hwang, M.D.

According to 2025 Medicare claims, Clara Hwang, M.D. (NPI: 1407978505) practices medical oncology in the Warren-Troy-Farmington Hills, MI market, with the plurality of this provider's patient population coming from Oakland, MI. This provider's primary affiliated billing organization is HENRY FORD HEALTH SYSTEM (NPI: 1891702833; TIN: 38-1357020) and primary practice location at 48202-2608. Hwang is affiliated with the Mosaic ACO (ACO ID: A5033), participating under the MSSP model.

Hwang's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 136 traditional Medicare patients, billed 422 HCPCS/CPT codes, and received $28,665 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,353 prescription claims across 223 beneficiaries totaling $5,232,086 in drug costs, led by Xtandi (Enzalutamide). 2019 DME data shows 32 claims. Open Payments data shows 84 records totaling $608,434. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $39,385 and ending at $28,665. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,657,011 to $5,232,086. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $342 to $591.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	148	543	$39,385
2016	135	409	$29,563
2017	131	443	$33,107
2018	128	415	$30,268
2019	180	592	$47,714
2020	148	400	$30,127
2021	150	701	$48,452
2022	141	338	$31,448
2023	141	284	$26,530
2024	136	422	$28,665

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	112	916	$1,657,011
2016	118	829	$1,807,040
2017	141	1,150	$3,017,421
2018	146	1,249	$4,974,042
2019	159	1,435	$5,431,133
2020	179	1,374	$6,100,466
2021	221	1,777	$6,991,493
2022	214	1,752	$8,485,102
2023	249	1,757	$8,327,553
2024	223	1,353	$5,232,086

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	26	$990
2019	N/R	32	$1,202
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	71	119	$110
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	13	14	$105
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	66	90	$65
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	16	37	$63
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	75	119	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	222	6,660	$2,690,135
Nubeqa	Darolutamide	66	1,980	$772,760
Abiraterone Acetate	Abiraterone Acetate	225	6,921	$342,920
Lenvima	Lenvatinib Mesylate	13	390	$297,339
Inlyta	Axitinib	13	381	$228,544

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	9	$1,677	Merck Sharp & Dohme LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	75	$606,757	Henry Ford Hospital
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Clara Hwang, M.D.?

Tedicare shows public-source Medicare data for Clara Hwang, M.D. (NPI 1407978505), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Clara Hwang, M.D. have ACO affiliation data?

Clara Hwang, M.D. is shown with ACO affiliation data for Mosaic ACO (MSSP, ACO ID A5033).

What billing organization is linked to Clara Hwang, M.D.?

Clara Hwang, M.D. is linked to HENRY FORD HEALTH SYSTEM (billing NPI 1891702833) in the available physician profile data.

Does Clara Hwang, M.D. have Open Payments data?

Clara Hwang, M.D. has 84 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.